Hagop M. Kantarjian, MD, discusses what experts should know regarding ponatinib and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Hagop M. Kantarjian, MD, professor, and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, and the Samsung Distinguished Leukemia Chair in Cancer Medicine, discusses what experts should know regarding ponatinib (Iclusig; Takeda) and blinatumomab (Blincyto; Amgen) in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
According to data discussed during the Tenth Annual Meeting of the Society of Hematologic Oncology, the combination induced deep responses and durable remissions in patients with Ph+ acute ALL.
Kantarjian notes how these findings may influence the future of this space as research pushes towards treating patients with non-chemotherapy regimens without the need of transplant, and with the use of ponatinib and blinatumomab.
Transcription:
0:08 | Ponatinib has shown significant activity in Philadelphia-positive ALL. When we use it at only 30 mg in combination with blinatumomab, we're getting fantastic results. I think in Philadelphia positive ALL, the tradition has been to use intensive chemotherapy with the BCR-ABL tyrosine kinase inhibitor and then move the patients to transplant, what we find is with ponatinib and blinatumomab, we're inducing the best molecular responses we've ever seen and we're reporting an estimated 3-year survival of 95% without the transplant.
0:49 | This is a major inflection point in the treatment of Philadelphia-positive ALL where we are advocating for a shift in the treatment from the combination of intensive chemotherapy TKI [tyrosine kinase inhibitor] and transplant to non-chemotherapy regimens without the need of transplant, and by using 2 targeted therapies, ponatinib and blinatumomab.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More